Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain [Seeking Alpha]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Play 8min Summary Rocket Pharmaceuticals' gene therapy treatments for rare diseases show promise, but high cash burn and potential dilution pose significant risks for investors. The company's Danon disease treatment, RP-A501, is a key focus, with promising Phase I results and progression to Phase II. Valuation is complicated by high costs of capital and reflexivity risk, with the company needing more funding in just over a year. Despite attractive valuation relative to peers, uncertainties in market penetration and reimbursement remain significant concerns in addition to reflexivity. We don't think the environment lends itself yet to plays like these. Looking for more investing ideas like this one? Get them exclusively at The Value Lab. Learn More » Black Friday Sale: Get 20% Off Bevan Goldswain/E+ via Getty Images Rocket Pharmaceuticals NASDAQ: RCKT ) actually looks relatively attractive. While prevalence figures are a little u
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $29.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire
- Rocket Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness Wire
RCKT
Earnings
- 11/7/24 - Beat
RCKT
Sec Filings
- 12/16/24 - Form SC
- 12/16/24 - Form 4
- 12/12/24 - Form 8-K
- RCKT's page on the SEC website